MA34251B1 - Derives amido-tropane - Google Patents

Derives amido-tropane

Info

Publication number
MA34251B1
MA34251B1 MA35398A MA35398A MA34251B1 MA 34251 B1 MA34251 B1 MA 34251B1 MA 35398 A MA35398 A MA 35398A MA 35398 A MA35398 A MA 35398A MA 34251 B1 MA34251 B1 MA 34251B1
Authority
MA
Morocco
Prior art keywords
glyt
compound
general formula
compounds
inhibitors
Prior art date
Application number
MA35398A
Other languages
English (en)
Inventor
Sabine Kolczewski
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34251B1 publication Critical patent/MA34251B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE GÉNÉRALE (I), DANS LAQUELLE R1, R2 ET R3 REPRÉSENTENT CHACUN INDÉPENDAMMENT UN ATOME D'HYDROGÈNE, UN ALKYLE INFÉRIEUR, UN ALKOXY INFÉRIEUR, UN CYCLOALKYLE, UN ALKYLE INFÉRIEUR SUBSTITUÉ PAR UN ATOME D'HALOGÈNE OU UN GROUPE S-(ALKYLE INFÉRIEUR) ; OU BIEN UN SEL D'ADDITION ACIDE PHARMACEUTIQUEMENT ACCEPTABLE, UN MÉLANGE RACÉMIQUE, OU L'ÉNANTIOMÈRE ET/OU L'ISOMÈRE OPTIQUE CORRESPONDANT DUDIT COMPOSÉ. LES COMPOSÉS DE FORMULE GÉNÉRALE (I) SE SONT AVÉRÉS ÊTRE DE BONS INHIBITEURS DU TRANSPORTEUR DE TYPE 1 DE LA GLYCINE (GLYT-1), ET PRÉSENTER UNE BONNE SÉLECTIVITÉ ENVERS LES INHIBITEURS DU TRANSPORTEUR DE TYPE 2 DE LA GLYCINE (GLYT-2). DE TELS COMPOSÉS PEUVENT ÊTRE UTILISÉS DANS LE CADRE DU TRAITEMENT DE TROUBLES NEUROLOGIQUES ET NEUROPSYCHIATRIQUES.
MA35398A 2010-06-22 2011-06-17 Derives amido-tropane MA34251B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10166757 2010-06-22
PCT/EP2011/060073 WO2011161006A1 (fr) 2010-06-22 2011-06-17 Dérivés amido-tropane

Publications (1)

Publication Number Publication Date
MA34251B1 true MA34251B1 (fr) 2013-05-02

Family

ID=44310862

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35398A MA34251B1 (fr) 2010-06-22 2011-06-17 Derives amido-tropane

Country Status (24)

Country Link
US (1) US8153653B2 (fr)
EP (1) EP2585456B1 (fr)
JP (1) JP5546684B2 (fr)
KR (1) KR101445016B1 (fr)
CN (1) CN102947297B (fr)
AR (1) AR081961A1 (fr)
AU (1) AU2011269145A1 (fr)
BR (1) BR112012032576A2 (fr)
CA (1) CA2801458C (fr)
CL (1) CL2012003552A1 (fr)
CO (1) CO6630160A2 (fr)
CR (1) CR20120614A (fr)
EA (1) EA201291374A1 (fr)
EC (1) ECSP12012347A (fr)
ES (1) ES2550831T3 (fr)
IL (1) IL222998A0 (fr)
MA (1) MA34251B1 (fr)
MX (1) MX2012013820A (fr)
PE (1) PE20130317A1 (fr)
PH (1) PH12012502339A1 (fr)
SG (1) SG186329A1 (fr)
TW (1) TWI417097B (fr)
WO (1) WO2011161006A1 (fr)
ZA (1) ZA201209248B (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3238414B2 (ja) * 1996-02-22 2001-12-17 ニューロサーチ・アクティーゼルスカブ トロパン―誘導体、その製造方法及びその使用方法
US5834484A (en) * 1997-03-12 1998-11-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Cocaine analogs
CN1874777B (zh) * 2003-09-09 2012-07-04 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物
FR2861076B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
FR2873693B1 (fr) * 2004-07-29 2006-09-15 Sanofi Synthelabo Derives d'amino-tropane, leur preparation et leur application en therapeutique
GB0428231D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
MX2007008190A (es) * 2005-01-06 2007-08-07 Hoffmann La Roche Fenil metanonas sustituidas con sulfanilo como inhibidores del transportador de glicina 1 (glyt-1) para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
US20100113545A1 (en) * 2007-02-01 2010-05-06 Steven Coulton Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2010020548A1 (fr) * 2008-08-20 2010-02-25 F. Hoffmann-La Roche Ag Antagonistes de glyt1

Also Published As

Publication number Publication date
CR20120614A (es) 2013-01-11
BR112012032576A2 (pt) 2016-11-22
PE20130317A1 (es) 2013-03-11
SG186329A1 (en) 2013-01-30
CN102947297A (zh) 2013-02-27
ZA201209248B (en) 2013-08-28
CO6630160A2 (es) 2013-03-01
EP2585456A1 (fr) 2013-05-01
PH12012502339A1 (en) 2013-02-11
AR081961A1 (es) 2012-10-31
TW201206438A (en) 2012-02-16
MX2012013820A (es) 2013-01-28
CA2801458C (fr) 2018-10-30
KR20130029414A (ko) 2013-03-22
JP2013529607A (ja) 2013-07-22
KR101445016B1 (ko) 2014-09-26
ECSP12012347A (es) 2013-01-31
CA2801458A1 (fr) 2011-12-29
TWI417097B (zh) 2013-12-01
US8153653B2 (en) 2012-04-10
US20110312993A1 (en) 2011-12-22
ES2550831T3 (es) 2015-11-12
CL2012003552A1 (es) 2013-04-12
IL222998A0 (en) 2013-02-03
HK1179606A1 (zh) 2013-10-04
AU2011269145A1 (en) 2012-11-08
CN102947297B (zh) 2015-12-16
WO2011161006A1 (fr) 2011-12-29
JP5546684B2 (ja) 2014-07-09
EA201291374A1 (ru) 2013-06-28
EP2585456B1 (fr) 2015-09-16

Similar Documents

Publication Publication Date Title
MA42442A (fr) Dérivés d&#39;éthynyle comme modulateurs du récepteur métabotropique au glutamate
PH12012500690A1 (en) Positive allosteric modulators (pam)
MA35133B1 (fr) Dérivés d&#39;éthynyle comme modulateurs allostériques positifs de mglur5
TN2010000248A1 (fr) Derives d&#39;indolinone et procede pour leur fabrication
BRPI0308696B8 (pt) composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
MA38272A1 (fr) Peptides en tant qu&#39;agonistes de l&#39;oxytocine
MA29245B1 (fr) Phenylmethanones heterocycliques substituees en tant qu&#39;inhibiteurs du transporteur 1 de la glycine
MA31447B1 (fr) Nouveaux dérivés d&#39;acide dicarboxylique utilisés comme agonistes du récepteur s1p1
SE0202134D0 (sv) Therapeutic agents
UA106692C2 (uk) ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
MA29688B1 (fr) Formulation d&#39;un inhibiteur de l&#39;agregation plaquettaire thienopyridine
MX2007006896A (es) Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
MA33802B1 (fr) Dérivés d&#39;éthynyle
MA38935B1 (fr) Dérivés de diazacarbazole à titre de ligands tau-pet
BR0209859A (pt) Derivados de imidazo[1,5-a]pirimido[5-4-d][1]benzazepina como moduladores de receptores de gaba a
EA200300718A1 (ru) Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
MA35113B1 (fr) 5-(phényl/pyridinyl-éthinyl)-2-pyridine/2 pyrimidine-carboxamides comme modulateur de mglur5
MA38885A1 (fr) Dérivés d&#39;éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
MA37719A1 (fr) Dérivés de pyrimidinone en tant qu&#39;agents anti-malaria
MX2007004639A (es) Derivados de imidazo-benzodiazepina.
MA38659B1 (fr) Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate
MA34251B1 (fr) Derives amido-tropane
MA38011B1 (fr) Dérivés d&#39;éthynyle comme modulateurs de l&#39;activité du récepteur mglur5
MA34250B1 (fr) Derives quinolizidine et indolizidine
MA37895A1 (fr) Dérivés d&#39;aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité